Multiple myeloma (MM) is a chronic hematologic malignancy that remains incurable,
because most patients eventually relapse or become refractory to current treatments. MM is …

Geriatric assessment management is a multidimensional tool used to evaluate prognosis for
clinical outcomes and targets for interventions in older adults with cancer receiving …

Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic
hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor-(CAR-) T cell …

Survival has improved in patients diagnosed with multiple myeloma (MM) over the last two
decades; however, there remains a paucity of data on the causes of death in MM patients …

Background T-cell–redirecting therapies, such as bispecific antibodies and chimeric antigen
receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells …

Abstract Purpose of Review As the treatment landscape for multiple myeloma (MM)
continues to expand at a rapid pace, management of older adults and frail patients becomes …

Minimal (or measurable) residual disease (MRD) negativity has emerged as one of the most
important prognostic tools in multiple myeloma (MM) and is associated with significant …

Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most
are based on clinical trial datasets. There is also limited data on the association between …

Multiple myeloma (MM) is a highly heterogeneous hematological malignancy originating
from B lymphocytes, with a high recurrence rate primarily due to drug resistance. 2-((1H …

Simple Summary Despite a lack of standardization and some open questions, a growing
body of evidence supports the use of frailty to optimize the clinical management of patients …